Background & aims: Type 2 diabetes mellitus (T2DM) is a progressive chronic non-communicable disease associated with various comorbidities; it is considered complex and therefore multifactorial strategies must be applied to reduce the associated risks. The aim of this before-and-after clinical trial was to evaluate the effects of adjuvant supplementation with probiotics in patients with T2DM.
Methods: The study included 20 patients aged >30 years with T2DM who were overweight or obese. The patients were administered probiotic supplements daily for 90 days, which consisted of probiotics Bacillus clausii microorganism strain. The patients' blood glucose parameters, lipid and intestinal microbiota profiles, blood pressure (BP), drug therapy, body mass index (BMI), and food tissue were evaluated.
Results: At the end of the study, we observed a statistically significant difference in blood glucose, increased high density lipoprotein (HDL) plasma levels, and improved intestinal microbiota profiles among the patients included in this study.
Conclusions: The results showed that probiotic supplementation significantly reduced fasting glycemia and promoted an improvement in their lipid profiles and intestinal health. These findings are promising and the use of probiotics may be an appropriate adjuvant therapy for glycemic control in patients with T2DM.
Keywords: Bacillus clausii; Chronic diseases; Microbiot; Probiotic.
Copyright © 2022 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights reserved.